Fresenius Hits Dr. Reddy's With Diprivan IP Suit

Law360, New York (May 24, 2013, 4:36 PM EDT) -- A subsidiary of Fresenius SE & Co. KGaA on Thursday accused the Indian pharmaceutical company Dr. Reddy’s Laboratories Ltd. and a U.S. unit of infringing four of its patents when Dr. Reddy’s applied to produce a generic version of the sedative Diprivan.

The suit, filed in Delaware federal court, claims Dr. Reddy’s has asked the U.S. Food and Drug Administration for approval of a generic version of the drug, despite having no reasonable basis to believe it wouldn’t be liable for infringing Fresenius’ patents.

The patents-in-suit...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.